Advertisement

Topics

LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

2015-03-09 01:13:43 | BioPortfolio

Summary

The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the essential hypertension.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Hypertension

Intervention

losartan potassium, Comparator: carvedilol, Comparator: losartan (+) hydrochlorothiazide (HCTZ), Comparator: carvedilol (+) hydrochlorothiazide

Status

Completed

Source

Merck Sharp & Dohme Corp.

Results (where available)

View Results

Links

Published on BioPortfolio: 2015-03-09T01:13:43-0400

Clinical Trials [926 Associated Clinical Trials listed on BioPortfolio]

A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension

The purpose of this study is to test the safety and effectiveness of Losartan as compared to Losartan/HCTZ in pediatric patients (6 to 17 years) with high blood pressure.

BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy

To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment.

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements

This study will qualify a functional model that can measure central blood pressure and vascular compliance effects through noninvasive means.

A Study to Investigate the Antihypertensive Efficacy of MK0954

After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This ...

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension

The purpose of this study was to evaluate the magnitude and durations of the antihypertensive effects of losartan using ambulatory blood pressure monitoring (ABPM), and to evaluate the saf...

PubMed Articles [590 Associated PubMed Articles listed on BioPortfolio]

Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism.

Losartan and berberine (BBR) are often simultaneously used for the treatment of senile diabetic nephropathy in clinics. However, the potential herb-drug interaction between losartan and BBR is unknown...

Formulation and optimization of mucoadhesive buccal patches of losartan potassium by using response surface methodology.

This study was undertaken with an aim to systematically design a model of factors that would yield an optimized sustained release dosage form of an anti-hypertensive agent, losartan potassium, using r...

Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?

Losartan is under evaluation for managing Marfan patients with aortic root dilatation. Cytochrome P450 (CYP) enzymes convert losartan to E3174 active metabolite. The aim of this study is to describe t...

The novel acid degradation products of losartan: Isolation and characterization using Q-TOF, 2D-NMR and FTIR.

Forced degradation of losartan potassium in acidic condition resulted into three potential unknown impurities. These unknown degradation products marked as LD-I, LD-II and LD-III were analyzed using a...

Losartan sensitizes selectively prostate cancer cell to ionizing radiation.

Losartan is an angiotensin II receptor (AT-II-R) blocker that is widely used by human for blood pressure regulation. Also, it has antitumor property. In this study, we investigated the radiosensitizin...

Medical and Biotech [MESH] Definitions

An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.

Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.

A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.

Stable potassium atoms that have the same atomic number as the element potassium, but differ in atomic weight. K-41 is a stable potassium isotope.

A delayed rectifier subtype of shaker potassium channels that is the predominant VOLTAGE-GATED POTASSIUM CHANNEL of T-LYMPHOCYTES.

More From BioPortfolio on "LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)"

Quick Search
Advertisement
 

Searches Linking to this Trial